How science is advancing

N-acetylaysteine (NAC) ,[object Object],[object Object],[object Object]

Clinical Trial ,[object Object]

Keeping in mind ,[object Object]

Design ,[object Object],[object Object],[object Object],[object Object]

Patients and Methods ,[object Object],[object Object],[object Object],[object Object]

Intervention ,[object Object],[object Object],[object Object]

Monitoring of the cycle ,[object Object],[object Object],[object Object]

Then ,[object Object],[object Object]

Success was monitored by ,[object Object],[object Object],[object Object]

Outcomes ,[object Object],[object Object],[object Object],[object Object],[object Object]

Results ,[object Object],[object Object],[object Object]

Demographics NS 28.5 ± 5.7 30.5 ± 2.6 BMI NS 99.2 ± 12.3 101.3 ± 12.4 B WT (Kg) NS 4.4 ± 2.6 5.0 ± 2.9 Duration (Ys) NS 28.4 ± 5.7 28.9 ± 4.7 Age (Ys) P value Group II Group I Variable

Hormonal profile NS 85.9 ± 14.1 81.9 ± 12 Fasting Glucose (mg/dL) NS 17.2 ± 4.4 18.8 ± 4.7 Fasting insulin (U/mL) NS 2.1 2.2 LH/FSH ratio P value Group II Group I Variable

Clinical outcomes of both groups

Pregnancy rates in patients who received NAC according to their insulin

How To Explain ,[object Object],[object Object],[object Object]

Potential biological activities of NAC ,[object Object],[object Object]

Side effects ,[object Object],[object Object],[object Object]

Conclusions ,[object Object],[object Object],[object Object]

Intervention ,[object Object]

[object Object],[object Object]

cost of medications ,[object Object],[object Object]

CONCLUSION II ,[object Object]

How science is advancing

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

En vedette

En vedette (7)

Similaire à How science is advancing

Similaire à How science is advancing (20)

Plus de Hesham Gaber

Plus de Hesham Gaber (20)

Dernier

Dernier (20)

How science is advancing